Abstract
The gastrin receptor antagonist, CR2093, competed with 125I-gastrin-17 (5 x 10(-10) M) for binding to gastrin receptors on the rat pancreatic adenocarcinoma, AR42J (CR2093 concentration inducing 50% of 125I-gastrin-17 binding (IC50) was 8 x 10(-5) M), on the human gastric adenocarcinoma, MKN45 (IC50 5.5 x 10(-5) M) and the human colo-rectal adenocarcinoma C523 (IC50 greater than 10(-4) M). Intravenous administration of CR2093 (40 mg kg-1 day-1) reduced the gastrin-17 stimulated growth of AR42J xenografts in nude mice to below that of the original basal growth (P = 0.0166 from basal and P = 0.0109 from gastrin stimulated growth). CR2093 administration also reduced the gastrin-stimulated growth of MKN45 xenografts (P = 0.045) but failed to inhibit the gastrin enhanced proliferation of C523 xenografts. This may be related to the affinity (Kd) of the gastrin receptors present on the xenograft lines as the Kds of the two xenografts inhibited by CR2093 were 4.6 x 10(-10) M (AR42J) and 1.2 x 10(-9) M (MKN45) respectively whereas the Kd of C523 was of higher affinity (2.2 x 10(-10) M). GR antagonists may be a viable therapeutic option for gastrin receptor positive, gastro-intestinal tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Watson, S., Crosbee, D., Morris, D. et al. Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth. Br J Cancer 65, 879–883 (1992). https://doi.org/10.1038/bjc.1992.184
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.184
This article is cited by
-
Gastrin activates autophagy and increases migration and survival of gastric adenocarcinoma cells
BMC Cancer (2017)
-
COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer
British Journal of Cancer (2002)
-
Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma
International journal of pancreatology (1998)